Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Brogden

Showing results (71-80 of 251) with videos related to

Pageof 26
Sort By:
Drugs|January 1, 1990
Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentialM M Buckley, R N Brogden
Drugs|February 1, 1986
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic useR N Brogden, R C Heel
Drugs|October 1, 1985
Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacyB N Prichard, R N Brogden
Drugs|March 1, 1994
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potentialH M Bryson, R N Brogden
Drugs|July 1, 1993
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitusK J Palmer, R N Brogden
Drugs & Aging|April 1, 1996
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial diseaseL B Barradell, R N Brogden
Drugs|October 1, 1990
Cefotaxime. An update of its pharmacology and therapeutic useP A Todd, R N Brogden
Drugs|May 1, 1994
Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemiaC M Spencer, R N Brogden
Drugs & Aging|December 1, 1995
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disordersJ E Frampton, R N Brogden
Drugs|April 1, 1988
Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic useR N Brogden, K L Goa
Pageof 26

Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
Drugs|January 1, 1990
Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentialM M Buckley, R N Brogden
Drugs|February 1, 1986
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic useR N Brogden, R C Heel
Drugs|October 1, 1985
Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacyB N Prichard, R N Brogden
Drugs|March 1, 1994
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potentialH M Bryson, R N Brogden
Drugs|July 1, 1993
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitusK J Palmer, R N Brogden
Drugs & Aging|April 1, 1996
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial diseaseL B Barradell, R N Brogden
Drugs|October 1, 1990
Cefotaxime. An update of its pharmacology and therapeutic useP A Todd, R N Brogden
Drugs|May 1, 1994
Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemiaC M Spencer, R N Brogden
Drugs & Aging|December 1, 1995
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disordersJ E Frampton, R N Brogden
Drugs|April 1, 1988
Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic useR N Brogden, K L Goa
Pageof 26